Medtronic (NYSE:MDT) Releases FY 2026 Earnings Guidance

Medtronic (NYSE:MDT) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 5.620-5.660 for the period, compared to the consensus earnings per share estimate of 5.640. The company issued revenue guidance of -, compared to the consensus revenue estimate of $36.0 billion.

Medtronic Stock Performance

Shares of MDT stock opened at $99.57 on Tuesday. Medtronic has a one year low of $79.55 and a one year high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The company has a 50 day moving average price of $99.25 and a 200 day moving average price of $96.53. The firm has a market capitalization of $127.65 billion, a price-to-earnings ratio of 26.84, a price-to-earnings-growth ratio of 2.62 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.33 by $0.03. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts anticipate that Medtronic will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s payout ratio is 76.55%.

Analyst Upgrades and Downgrades

MDT has been the topic of several research analyst reports. JPMorgan Chase & Co. lifted their price objective on Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Needham & Company LLC raised shares of Medtronic from a “hold” rating to a “buy” rating and set a $121.00 price target on the stock in a research report on Monday, February 9th. Jefferies Financial Group reiterated a “hold” rating and set a $110.00 price objective on shares of Medtronic in a research note on Wednesday, November 19th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Sixteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $111.21.

Institutional Investors Weigh In On Medtronic

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quadrant Capital Group LLC boosted its stake in shares of Medtronic by 0.3% during the 4th quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock valued at $3,120,000 after buying an additional 101 shares during the last quarter. Rossby Financial LCC boosted its stake in Medtronic by 5.1% during the 4th quarter. Rossby Financial LCC now owns 2,193 shares of the medical technology company’s stock valued at $211,000 after acquiring an additional 107 shares during the last quarter. Mitchell Mcleod Pugh & Williams Inc. grew its holdings in Medtronic by 2.0% during the 4th quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 6,043 shares of the medical technology company’s stock worth $622,000 after acquiring an additional 117 shares in the last quarter. Florida Financial Advisors LLC grew its holdings in Medtronic by 4.8% during the 2nd quarter. Florida Financial Advisors LLC now owns 2,683 shares of the medical technology company’s stock worth $234,000 after acquiring an additional 122 shares in the last quarter. Finally, CYBER HORNET ETFs LLC increased its position in shares of Medtronic by 3.9% in the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,502 shares of the medical technology company’s stock worth $334,000 after purchasing an additional 130 shares during the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).